期刊文献+

小剂量阿仑膦酸钠治疗骨质疏松症疗效观察 被引量:7

下载PDF
导出
摘要 目的观察小剂量阿仑膦酸钠治疗骨质疏松症的疗效、安全性和依从性。方法选择2014年12月至2016年12月于深圳市第二人民医院内分泌科诊断为骨质疏松症的患者20例,年龄34~76岁,予以阿仑膦酸钠70 mg/周、钙尔奇600 mg/d及骨化三醇0.25μg/d治疗3个月后,阿仑膦酸钠减量为70 mg/2周继续治疗9个月。观察治疗前后患者的骨转换标志物(BTMs)的变化、骨密度变化及治疗过程中有无骨质疏松性骨折发生、相关副作用及依从性。结果治疗3个月后患者的骨转换指标较治疗前明显降低,Ⅰ型胶原C末端肽(β-CTX)由(0.60±0.39)ng/m L降为(0.10±0.07)ng/m L,I型原胶原N-端前肽(P1NP)由(64.02±40.22)ng/m L降为(25.63±41.93)ng/m L,差异均有统计学意义(P<0.05);改为小剂量阿仑膦酸钠70 mg/2周继续治疗至12个月后,骨转换指标与治疗前比较仍低,β-CTX为(0.14±0.06)ng/m L,P1NP为(21.18±5.09)ng/m L,差异均有统计学意义(P<0.05)。所有患者的骨密度较治疗前有所提高,但差异均无统计学意义(P>0.05);所有患者均无骨质疏松性骨折发生,无相关副作用出现,治疗依从性好。结论小剂量阿仑膦酸钠治疗骨质疏松症安全有效,依从性好。
出处 《海南医学》 CAS 2018年第15期2172-2174,共3页 Hainan Medical Journal
  • 相关文献

参考文献5

二级参考文献39

  • 1Van staa TP,Leufkens HGM,Cooper C,et al.The epidemiologyof corticosteroid-induced osteoporosis:a meta-analysis.OsteoporosisInt,2002,13(10):777-787.
  • 2Schacht E,Dukas L,Richy F,et al.Combined therapies inosteoporosis:bisphosphonates and vitamin D-hormone analogs.JMusculoskelet Neuronal Interact,2007,7(2):174-184.
  • 3Ettinger MP,Gallagher R,MacCosbe PE,et al.Medication persistewith weekly versus daily doses of orally administerbisphosphonates.Endocr Pract,2006,12(5):522-528.
  • 4Pandy R,Quinn J,Sabokbar A,et al.Bisphosphonate inhibition ofbone resorption by particulate biomatorial-associated maerophages.Acta Orthop Scand,1996,67:221-228.
  • 5Burgess TL,Qian YX,Kaufman S,et al.The ligand forosteoprotegerin(OPGL)directly activates mature osteoclasts.CellBiol,1999,145:527-538.
  • 6Cranney A,Guyatt G,Griffitll L,et al.Meta-analyses of therapiesfor postmenopausal osteoporosis.IX:Summary of meta-analyses oftherapies for postmenopausal osteoporosis.Endocr Rev,2002,23(4):570-578.
  • 7Black DM,Cummings SR,karpf DB,et al.Randomised trial ofeffect of alendronate on risk of fracture in women with existingvertebral fractures.Lancet,1996,348(9041):1535-1541.
  • 8Adachi JD,Saag KG,Delmas PD,et al.Two-year effects ofalendronate on bone mineral density and vertebral fracture in patientsreceving gulcocorticoids:a randomized,double-blind,placebo-controlled extension trial.Arthritis Rheum,2001,44(13):202-211.
  • 9Bone HG,Adami S,Rizzoli R,et al.Weekly administration ofalendronate:rationale and plan for clinical assessment.Clin Ther,2000,22(11):15-28.
  • 10Peter CP,Handt LK,Smith SM,et al.Esophageal irritation due toalendronate sodium tablets:possible mechanisms.Dig Dis Sci,1998,43(9):98-102.

共引文献1434

同被引文献51

引证文献7

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部